Table 4.
Odds ratios of colorectal cancer per 50th percentile increase in concentration of leptin, adiponectin, and sTNFR2 stratified by lifestyle, metabolic, and inflammatory factors in CLUE II
| Cases/controls | Adiponectin | Leptin | sTNFR2 | Cases/controls | Adiponectin | Leptin | sTNFR2 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR* | 95%CI | OR* | 95%CI | OR* | 95%CI | OR* | 95%CI | OR* | 95%CI | OR* | 95%CI | |||
| BMI (kg/m2) | ||||||||||||||
| < 25.7 | 34/34 | 1.08 | 0.31–3.74 | 0.66 | 0.05–8.34 | 1.12 | 0.84–1.49 | 55/62 | 0.10 | 0.01–2.02 | 0.42 | 0.00–90.68 | 0.94 | 0.67–1.31 |
| ≥ 25.7 | 55/55 | 0.72 | 0.25–2.09 | 1.27 | 0.16–10.25 | 1.20 | 0.98–1.48 | 49/42 | 0.98 | 0.04–24.27 | 0.64 | 0.00–93.21 | 1.09 | 0.77–1.54 |
| p-interaction | 0.6 | 0.6 | 0.8 | 0.4 | 0.7 | 0.6 | ||||||||
| Adult weight gain (lbs)** | ||||||||||||||
| < 25 | 34/40 | 0.96 | 0.26–3.53 | 0.15 | 0.01–3.58 | 1.53 | 1.14–2.05 | 54/54 | 0.24 | 0.01–4.16 | 0.32 | 0.00–44.10 | 1.05 | 0.74–1.50 |
| ≥ 25 | 55/48 | 0.79 | 0.26–2.34 | 1.42 | 0.20–10.17 | 0.99 | 0.79–1.23 | 49/50 | 0.75 | 0.03–18.70 | 0.31 | 0.00–81.95 | 1.07 | 0.76–1.51 |
| p-interaction | 0.6 | 0.6 | 0.03 | 0.5 | 0.9 | 0.7 | ||||||||
| NSAID use | ||||||||||||||
| No | 69/61 | 1.00 | 0.42–2.40 | 1.21 | 0.22–6.76 | 1.16 | 0.97–1.39 | 84/81 | 0.38 | 0.03–4.16 | 0.60 | 0.01–34.10 | 0.90 | 0.69–1.17 |
| Yes | 20/28 | 0.12 | 0.01–1.31 | 0.17 | 0.00–6.89 | 1.61 | 0.98–2.65 | 20/23 | 0.25 | 0.00–38.94 | 0.48 | 0.00–2428.73 | 1.56 | 0.85–2.87 |
| p-interaction | 0.2 | 0.6 | 0.6 | 0.9 | 0.9 | 0.1 | ||||||||
| CRP (mg/L) | ||||||||||||||
| < 1.77 | 20/35 | 0.90 | 0.11–7.06 | 0.96 | 0.05–19.91 | 1.49 | 1.00–2.20 | 38/44 | 0.25 | 0.01–6.73 | 0.03 | 0.00–18.25 | 0.90 | 0.59–1.36 |
| ≥ 1.77 | 51/35 | 1.26 | 0.46–3.45 | 1.24 | 0.15–10.06 | 1.08 | 0.85–1.36 | 51/44 | 0.13 | 0.00–3.71 | 0.99 | 0.01–154.32 | 1.06 | 0.76–1.47 |
| p-interaction | 0.9 | 0.6 | 0.5 | 0.9 | 0.5 | 0.6 | ||||||||
| IL-6 (pg/mL) | ||||||||||||||
| < 1.773 | 20/27 | 1.23 | 0.20–7.45 | 0.67 | 0.03–17.39 | 1.48 | 0.90–2.42 | 32/51 | 0.15 | 0.00–7.85 | 0.00 | 0.00–4.58 | 0.95 | 0.62–1.46 |
| ≥ 1.773 | 51/43 | 1.04 | 0.36–2.97 | 0.78 | 0.10–6.07 | 1.11 | 0.90–1.36 | 57/36 | 0.17 | 0.01–2.81 | 1.23 | 0.01–130.53 | 1.06 | 0.76–1.46 |
| p-interaction | 0.6 | 0.8 | 0.3 | 0.9 | 0.1 | 0.2 | ||||||||
| Insulin (mU/L) | ||||||||||||||
| < 13.544 | 33/29 | 1.54 | 0.38–6.29 | 1.98 | 0.16–23.82 | 1.21 | 0.92–1.58 | 46/50 | 0.33 | 0.02–6.85 | 0.27 | 0.00–54.90 | 0.90 | 0.63–1.30 |
| ≥ 13.544 | 37/41 | 0.80 | 0.22–2.86 | 0.57 | 0.04–7.50 | 1.19 | 0.90–1.59 | 43/38 | 0.11 | 0.00–5.40 | 0.26 | 0.00–108.25 | 1.09 | 0.75–1.60 |
| p-interaction | 0.5 | 0.8 | 0.7 | 0.7 | 0.9 | 0.8 | ||||||||
| HbA1c (%) | ||||||||||||||
| < 5.7 | 42/50 | 2.56 | 0.72–9.15 | 4.01 | 0.40–40.30 | 1.18 | 0.92–1.52 | 48/59 | 0.21 | 0.01–4.79 | 0.05 | 0.00–10.19 | 1.01 | 0.70–1.44 |
| ≥ 5.7 | 29/20 | 0.68 | 0.18–2.55 | 0.19 | 0.01–3.74 | 1.25 | 0.92–1.70 | 41/29 | 0.13 | 0.00–4.40 | 1.65 | 0.00–1013.88 | 0.99 | 0.68–1.44 |
| p-interaction | 0.1 | 0.5 | 0.9 | 0.7 | 0.3 | 0.8 | ||||||||
| No diabetes medication use | 81/84 | 0.89 | 0.39–2.03 | 0.90 | 0.19–4.19 | 1.17 | 0.98–1.38 | 96/101 | 0.53 | 0.06–4.51 | 0.82 | 0.02–30.38 | 1.00 | 0.78–1.27 |
| Smoking status | ||||||||||||||
| Never | 29/35 | 0.53 | 0.12–2.34 | 5.55 | 0.36–85.39 | 1.23 | 0.86–1.76 | 65/66 | 0.20 | 0.01–2.81 | 0.38 | 0.00–46.87 | 1.02 | 0.76–1.38 |
| Ever | 60/54 | 1.02 | 0.38–2.75 | 0.31 | 0.04–2.46 | 1.15 | 0.95–1.39 | 39/38 | 0.80 | 0.02–26.94 | 0.22 | 0.00–57.68 | 1.02 | 0.70–1.49 |
| p-interaction | 0.6 | 0.1 | 0.3 | 0.7 | 0.9 | 0.9 | ||||||||
*
Per 50th percentile increase in biomarker concentration with the 25th to 75th delta based on the distribution for men and women combined estimated using unconditional logistic regression adjusted for the matching factors (age, race, date of blood draw, time since last meal), mutually for leptin, adiponectin, sTNFR2, and for BMI (continuous)
**
from age 21 to baseline in 1989